Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Neurogene Inc.NLTX · Entity 5160 | Director | May 05, 2020 | May 07, 2020 |
| Social Capital Suvretta Holdings Corp. IIDNAB · Entity 125597 | Director | September 24, 2021 | September 24, 2021 |
| Taysha Gene Therapies, Inc.TSHA · Entity 4549 | Director · Chief Executive Officer | January 23, 2026 | January 27, 2026 |
| Ventas, Inc.VTR · Entity 3044 | Director | May 13, 2026 | May 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Neurogene Inc.
Report date May 05, 2020 · Filed May 07, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.84 · Expires 2030-05-05 | Direct | 25,000 |
Reported balance
After 2020-05-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-05 · Grant · Acquired 25,000 · Balance 25,000 F1: The option vests as to 1/12 of the total shares monthly beginning June 5, 2020 until the option is fully vested on May 5, 2021, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 1/12 of the total shares monthly beginning June 5, 2020 until the option is fully vested on May 5, 2021, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Social Capital Suvretta Holdings Corp. II
Report date September 24, 2021 · Filed September 24, 2021
This filing explicitly reported no securities owned.
Taysha Gene Therapies, Inc.
Report date January 23, 2026 · Filed January 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,908,257 |
Ending reported balance
After 2026-01-26 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-01-23 · Sale · Disposed 136,789 · Balance 2,949,569 F1: The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Row 2 · 2026-01-26 · Sale · Disposed 41,312 · Balance 2,908,257 F1: The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only. F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,535,545 |
Reported balance
Holding disclosure · report date 2026-01-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,535,545 F4: The securities are held by Nolan Capital, LLC (the "LLC"). The Reporting Person is the President of the LLC and has shared voting and investment power with respect to the shares held by the LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive.
F4: The securities are held by Nolan Capital, LLC (the "LLC"). The Reporting Person is the President of the LLC and has shared voting and investment power with respect to the shares held by the LLC.
Ventas, Inc.
Report date May 13, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,181 |
Reported balance
After 2026-05-13 transaction · row 1
1 source rowRow 1 · 2026-05-13 · Grant · Acquired 2,047 · Balance 26,181 F1: Restricted stock units granted by Issuer pursuant to the Ventas, Inc. 2022 Incentive Plan. The restricted stock units vest on the earlier of the one-year anniversary of the grant date or the date of Issuer's 2027 Annual Meeting of Stockholders. F2: Represents the closing price per share of Issuer's common stock as of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units granted by Issuer pursuant to the Ventas, Inc. 2022 Incentive Plan. The restricted stock units vest on the earlier of the one-year anniversary of the grant date or the date of Issuer's 2027 Annual Meeting of Stockholders.
F2: Represents the closing price per share of Issuer's common stock as of the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AveXis, Inc.
Report date May 15, 2018 · Filed May 15, 2018
Section 16 reporting ended · disclosed 2018-05-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 1
1 source rowRow 1 · 2018-05-15 · Disposition to issuer · Disposed 11,000 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F2: Represents 11,000 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.94 · Expires 2025-06-10 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-05-15 · Disposition to issuer · Disposed 728,300 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.61 · Expires 2026-06-20 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-05-15 · Disposition to issuer · Disposed 110,000 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.24 · Expires 2027-05-10 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-05-15 · Disposition to issuer · Disposed 96,000 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $133.80 · Expires 2028-03-13 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-05-15 · Disposition to issuer · Disposed 44,000 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash.
F2: Represents 11,000 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU.
F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2026 Filed May 15, 2026 21:01 UTC | Ventas, Inc. VTR · Entity 3044 | GrantCommon Stock | 2,047 | $90.35 | $184,946.45 |
DisclosureSEC source: 0001569926-26-000012 · wk-form4_1778878864.xml · nonDerivative · entry 1 Nolan Sean P. · CIK 0001569926 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,181 F1 · shares: Restricted stock units granted by Issuer pursuant to the Ventas, Inc. 2022 Incentive Plan. The restricted stock units vest on the earlier of the one-year anniversary of the grant date or the date of Issuer's 2027 Annual Meeting of Stockholders. F2 · price: Represents the closing price per share of Issuer's common stock as of the grant date. Read SEC document |
| January 26, 2026 Filed Jan 27, 2026 21:05 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 41,312 | $4.61 | $190,448.32 |
DisclosureSEC source: 0001569926-26-000008 · form4-01272026_040103.xml · nonDerivative · entry 2 Nolan Sean P. · CIK 0001569926 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,908,257 F1 · shares: The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive. Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 21:05 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 136,789 | $4.75 | $649,747.75 |
DisclosureSEC source: 0001569926-26-000008 · form4-01272026_040103.xml · nonDerivative · entry 1 Nolan Sean P. · CIK 0001569926 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,949,569 F1 · shares: The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:45 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantEmployee Stock Option (right to buy) · Derivative | 648,000 | $0.00 Strike: $4.86 | $0.00 |
DisclosureSEC source: 0001569926-26-000002 · form4-01142026_040103.xml · derivative · entry 3 Nolan Sean P. · CIK 0001569926 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 648,000 Underlying: Common Stock · 648,000 shares Expires 2036-01-12 F3 · derivative.exercise_date: 25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:45 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantCommon Stock | 1,008,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001569926-26-000002 · form4-01142026_040103.xml · nonDerivative · entry 1 Nolan Sean P. · CIK 0001569926 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,086,358 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| May 13, 2025 Filed May 15, 2025 20:54 UTC | Ventas, Inc. VTR · Entity 3044 | GrantCommon Stock | 2,882 | $64.18 | $184,966.76 |
DisclosureSEC source: 0000740260-25-000175 · wk-form4_1747342442.xml · nonDerivative · entry 1 Nolan Sean P. · CIK 0001569926 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,134 F1 · shares: Restricted stock units granted by Issuer pursuant to the Ventas, Inc. 2022 Incentive Plan. The restricted stock units vest on the earlier of the one-year anniversary of the grant date or the date of Issuer's 2026 Annual Meeting of Stockholders. F2 · price: Represents the closing price per share of Issuer's common stock as of the grant date. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 22:38 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantEmployee Stock Option (right to buy) · Derivative | 892,500 | $0.00 Strike: $1.85 | $0.00 |
DisclosureSEC source: 0001415889-25-000599 · form4-01032025_100137.xml · derivative · entry 3 Nolan Sean P. · CIK 0001569926 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 892,500 Underlying: Common Stock · 892,500 shares Expires 2035-01-02 F3 · derivative.exercise_date: 25% of the total number of shares underlying the option shall vest and become exercisable on January 2, 2026 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 22:38 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantCommon Stock | 892,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000599 · form4-01032025_100137.xml · nonDerivative · entry 1 Nolan Sean P. · CIK 0001569926 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,078,358 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSU grant was approved by the Issuer's compensation committee of the board of directors and will be effective as of the date the Issuer has an effective Registration Statement on Form S-8 registering the shares available for issuance under the 2020 Stock Incentive Plan. The RSUs will vest in four equal annual installments beginning on January 2, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| May 14, 2024 Filed May 16, 2024 21:01 UTC | Ventas, Inc. VTR · Entity 3044 | GrantCommon Stock | 3,648 | $47.96 | $174,958.08 |
DisclosureSEC source: 0000740260-24-000162 · wk-form4_1715893277.xml · nonDerivative · entry 1 Nolan Sean P. · CIK 0001569926 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,252 F1 · shares: Restricted stock units granted by Issuer pursuant to the Ventas, Inc. 2022 Incentive Plan. The restricted stock units vest on the earlier of the one-year anniversary of the grant date or the date of Issuer's 2025 Annual Meeting of Stockholders. F2 · price: Represents the closing price per share of Issuer's common stock as of the date of the grant. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:41 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantEmployee Stock Option (right to buy) · Derivative | 1,184,688 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001209191-24-000807 · doc4.xml · derivative · entry 3 Nolan Sean P. · CIK 0001569926 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,184,688 Underlying: Common Stock · 1,184,688 shares Expires 2034-01-02 F3 · derivative.exercise_date: 25% of the total number of shares underlying the option shall vest and become exercisable on January 2, 2025 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:41 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantCommon Stock | 1,184,688 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000807 · doc4.xml · nonDerivative · entry 1 Nolan Sean P. · CIK 0001569926 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,185,858 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 2, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 21:46 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantEmployee Stock Option (right to buy) · Derivative | 466,550 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001209191-23-058971 · doc4.xml · derivative · entry 1 Nolan Sean P. · CIK 0001569926 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 466,550 Underlying: Common Stock · 466,550 shares Expires 2033-12-14 F1 · derivative.exercise_date: The compensation committee of the board of directors of the Issuer certified achievement of certain performance criteria such that 70% of the option shares subject to the performance-based stock option award were earned. The shares underlying the earned potion of the option shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| August 16, 2023 Filed Aug 17, 2023 00:52 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | PurchaseCommon Stock | 444,444 | $0.90 | $399,999.60 |
DisclosureSEC source: 0001209191-23-046150 · doc4.xml · nonDerivative · entry 1 Nolan Sean P. · CIK 0001569926 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,535,545 F1 · ownership.nature: The securities are held by Nolan Capital, LLC (the "LLC"). The Reporting Person is the President of the LLC and has shared voting and investment power with respect to the shares held by the LLC. Read SEC document |
| May 16, 2023 Filed May 18, 2023 20:48 UTC | Ventas, Inc. VTR · Entity 3044 | GrantCommon Stock | 3,835 | $45.63 | $174,991.05 |
DisclosureSEC source: 0000740260-23-000123 · wf-form4_168444289623867.xml · nonDerivative · entry 1 Nolan Sean P. · CIK 0001569926 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,604 F1 · shares: Restricted stock units granted by Issuer pursuant to the Ventas, Inc. 2022 Incentive Plan. The restricted stock units vest on the earlier of the one-year anniversary of the grant date or the date of the Issuer's 2024 Annual Meeting of Stockholders. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 21:51 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (right to buy) · Derivative | 1,106,131 | $0.00 Strike: $2.26 | $0.00 |
DisclosureSEC source: 0001209191-23-001020 · doc4.xml · derivative · entry 1 Nolan Sean P. · CIK 0001569926 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,106,131 Underlying: Common Stock · 1,106,131 shares Expires 2032-12-30 F1 · derivative.exercise_date: 25% of the total number of shares underlying the option shall vest and become exercisable on December 16, 2023 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 20:38 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (right to buy) · Derivative | 15,500 | $0.00 Strike: $2.81 | $0.00 |
DisclosureSEC source: 0001209191-22-038689 · doc4.xml · derivative · entry 1 Nolan Sean P. · CIK 0001569926 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Underlying: Common Stock · 15,500 shares Expires 2032-06-17 F1 · derivative.exercise_date: The shares vest on the earlier of June 17, 2023 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director though the applicable vesting date. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 20:50 UTC | Ventas, Inc. VTR · Entity 3044 | GrantCommon Stock | 3,056 | $57.25 | $174,956.00 |
DisclosureSEC source: 0000740260-22-000111 · wf-form4_165126533152098.xml · nonDerivative · entry 1 Nolan Sean P. · CIK 0001569926 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,769 F1 · shares: Restricted stock granted by Issuer pursuant to the Ventas, Inc. 2012 Incentive Plan. The restricted stock vests in two equal annual installments on the date of the Issuer's 2023 Annual Meeting of Stockholders and the date of the Issuer's 2024 Annual Meeting of Stockholders. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 21:02 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (right to buy) · Derivative | 15,500 | $0.00 Strike: $25.04 | $0.00 |
DisclosureSEC source: 0001209191-21-042107 · doc4.xml · derivative · entry 1 Nolan Sean P. · CIK 0001569926 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Underlying: Common Stock · 15,500 shares Expires 2031-06-17 F1 · derivative.exercise_date: The shares vest on the earlier of June 17, 2022 or the next annual stockholders meeting, subject to continued service as a director though the applicable vesting date. Read SEC document |
| May 25, 2021 Filed May 27, 2021 21:28 UTC | Ventas, Inc. VTR · Entity 3044 | GrantCommon Stock | 3,158 | $0.00 | $0.00 |
DisclosureSEC source: 0000740260-21-000134 · wf-form4_162215084775256.xml · nonDerivative · entry 1 Nolan Sean P. · CIK 0001569926 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,713 F1 · shares: Restricted stock granted by Issuer pursuant to the Ventas, Inc. 2012 Incentive Plan. The restricted stock vests in two equal annual installments on the date of the Issuer's 2022 Annual Meeting of Stockholders and the date of the Issuer's 2023 Annual Meeting of Stockholders. Read SEC document |
| May 20, 2021 Filed May 24, 2021 12:39 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | PurchaseCommon Stock | 1,170 | $22.35 | $26,149.50 |
DisclosureSEC source: 0001209191-21-035165 · doc4.xml · nonDerivative · entry 1 Nolan Sean P. · CIK 0001569926 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,170 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.04 to $22.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Sep 30, 2020 20:38 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | ConversionSeries B Preferred Stock · Derivative | 1,470 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052462 · doc4.xml · derivative · entry 4 Nolan Sean P. · CIK 0001569926 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,601 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date. F2 · ownership.nature: The securities are held by Nolan Capital, LLC (the "LLC"). The Reporting Person is the President of LLC, and is deemed to have sole voting and investment power with respect to the securities. Read SEC document |
| September 28, 2020 Filed Sep 30, 2020 20:38 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | ConversionSeries A Preferred Stock · Derivative | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052462 · doc4.xml · derivative · entry 3 Nolan Sean P. · CIK 0001569926 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,089,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date. F2 · ownership.nature: The securities are held by Nolan Capital, LLC (the "LLC"). The Reporting Person is the President of LLC, and is deemed to have sole voting and investment power with respect to the securities. Read SEC document |
| September 28, 2020 Filed Sep 30, 2020 20:38 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | ConversionCommon Stock | 1,601 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-052462 · doc4.xml · nonDerivative · entry 2 Nolan Sean P. · CIK 0001569926 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,091,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date. F2 · ownership.nature: The securities are held by Nolan Capital, LLC (the "LLC"). The Reporting Person is the President of LLC, and is deemed to have sole voting and investment power with respect to the securities. Read SEC document |
| September 28, 2020 Filed Sep 30, 2020 20:38 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | ConversionCommon Stock | 1,089,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-052462 · doc4.xml · nonDerivative · entry 1 Nolan Sean P. · CIK 0001569926 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,089,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date. F2 · ownership.nature: The securities are held by Nolan Capital, LLC (the "LLC"). The Reporting Person is the President of LLC, and is deemed to have sole voting and investment power with respect to the securities. Read SEC document |
| September 23, 2020 Filed Sep 25, 2020 21:13 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (right to buy) · Derivative | 31,000 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052115 · doc4.xml · derivative · entry 1 Nolan Sean P. · CIK 0001569926 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 31,000 shares Expires 2030-09-23 F1 · derivative.exercise_date: The shares subject to the Option vest in 36 equal monthly installments, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| July 21, 2020 Filed Feb 17, 2026 22:00 UTC | Ventas, Inc. VTR · Entity 3044 | PurchaseCommon Stock | 37 | $34.21 | $1,265.93 |
DisclosureSEC source: 0001569926-26-000010 · wk-form5_1771365641.xml · nonDerivative · entry 4 Nolan Sean P. · CIK 0001569926 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 87 F2 · ownership.nature: Represents shares acquired by the Elizabeth A. Nolan Dec of Trust. Read SEC document |
| July 21, 2020 Filed Feb 17, 2026 22:00 UTC | Ventas, Inc. VTR · Entity 3044 | PurchaseCommon Stock | 27 | $34.21 | $923.78 |
DisclosureSEC source: 0001569926-26-000010 · wk-form5_1771365641.xml · nonDerivative · entry 2 Nolan Sean P. · CIK 0001569926 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By LLC Disclosed balance after: 63 F1 · ownership.nature: Represents shares acquired by the Nolan Family Investments LLC. Read SEC document |
| May 18, 2020 Filed May 20, 2020 20:53 UTC | Ventas, Inc. VTR · Entity 3044 | GrantCommon Stock | 5,424 | $0.00 | $0.00 |
DisclosureSEC source: 0000740260-20-000110 · wf-form4_159000798787099.xml · nonDerivative · entry 1 Nolan Sean P. · CIK 0001569926 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,555 F1 · shares: Restricted stock granted by Issuer pursuant to the Ventas, Inc. 2012 Incentive Plan. This restricted stock vests in two equal annual installments on the date of the Issuer's 2021 Annual Meeting of Stockholders and the date of the Issuer's 2022 Annual Meeting of Stockholders. Read SEC document |
| May 05, 2020 Filed May 7, 2020 20:25 UTC | Neurogene Inc. NLTX · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $12.84 | $0.00 |
DisclosureSEC source: 0001209191-20-027679 · doc4.xml · derivative · entry 1 Nolan Sean P. · CIK 0001569926 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-05-05 F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning June 5, 2020 until the option is fully vested on May 5, 2021, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2020 Filed Feb 17, 2026 22:00 UTC | Ventas, Inc. VTR · Entity 3044 | PurchaseCommon Stock | 50 | $27.70 | $1,384.83 |
DisclosureSEC source: 0001569926-26-000010 · wk-form5_1771365641.xml · nonDerivative · entry 3 Nolan Sean P. · CIK 0001569926 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 50 F2 · ownership.nature: Represents shares acquired by the Elizabeth A. Nolan Dec of Trust. Read SEC document |
| April 20, 2020 Filed Feb 17, 2026 22:00 UTC | Ventas, Inc. VTR · Entity 3044 | PurchaseCommon Stock | 36 | $27.70 | $997.07 |
DisclosureSEC source: 0001569926-26-000010 · wk-form5_1771365641.xml · nonDerivative · entry 1 Nolan Sean P. · CIK 0001569926 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By LLC Disclosed balance after: 36 F1 · ownership.nature: Represents shares acquired by the Nolan Family Investments LLC. Read SEC document |
| October 10, 2019 Filed Oct 15, 2019 20:45 UTC | Neurogene Inc. NLTX · Entity 5160 | GrantStock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0000899243-19-025572 · doc4.xml · derivative · entry 1 Nolan Sean P. · CIK 0001569926 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-10-09 F1 · derivative.exercise_date: The options will vest as to 1/3 of the total number of shares underlying the options on each of October 10, 2020, October 10, 2021 and October 10, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| July 26, 2019 Filed Jul 29, 2019 20:58 UTC | Ventas, Inc. VTR · Entity 3044 | GrantCommon Stock | 2,131 | $67.03 | $142,840.93 |
DisclosureSEC source: 0000740260-19-000142 · wf-form4_156443388352571.xml · nonDerivative · entry 1 Nolan Sean P. · CIK 0001569926 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,131 F1 · shares: Restricted stock granted by Issuer pursuant to the Ventas, Inc. 2012 Incentive Plan. This restricted stock vests in two equal annual installments beginning on the first anniversary of the date of the grant. Read SEC document |
| May 15, 2018 Filed May 15, 2018 12:38 UTC | AveXis, Inc. AVXS · Entity 166664 | Disposition to issuerStock Option (Right to Buy) · Derivative | 44,000 | $0.00 Strike: $133.80 | $0.00 |
DisclosureSEC source: 0001209191-18-030127 · doc4.xml · derivative · entry 5 Nolan Sean P. · CIK 0001569926 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,000 shares Expires 2028-03-13 F1 · kind: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. Read SEC document |
| May 15, 2018 Filed May 15, 2018 12:38 UTC | AveXis, Inc. AVXS · Entity 166664 | Disposition to issuerStock Option (Right to Buy) · Derivative | 96,000 | $0.00 Strike: $77.24 | $0.00 |
DisclosureSEC source: 0001209191-18-030127 · doc4.xml · derivative · entry 4 Nolan Sean P. · CIK 0001569926 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 96,000 shares Expires 2027-05-10 F1 · kind: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. Read SEC document |
| May 15, 2018 Filed May 15, 2018 12:38 UTC | AveXis, Inc. AVXS · Entity 166664 | Disposition to issuerStock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $42.61 | $0.00 |
DisclosureSEC source: 0001209191-18-030127 · doc4.xml · derivative · entry 3 Nolan Sean P. · CIK 0001569926 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 110,000 shares Expires 2026-06-20 F1 · kind: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. Read SEC document |
| May 15, 2018 Filed May 15, 2018 12:38 UTC | AveXis, Inc. AVXS · Entity 166664 | Disposition to issuerStock Option (Right to Buy) · Derivative | 728,300 | $0.00 Strike: $15.94 | $0.00 |
DisclosureSEC source: 0001209191-18-030127 · doc4.xml · derivative · entry 2 Nolan Sean P. · CIK 0001569926 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 728,300 shares Expires 2025-06-10 F1 · kind: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. Read SEC document |
| May 15, 2018 Filed May 15, 2018 12:38 UTC | AveXis, Inc. AVXS · Entity 166664 | Disposition to issuerCommon Stock | 11,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-030127 · doc4.xml · nonDerivative · entry 1 Nolan Sean P. · CIK 0001569926 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F2 · shares: Represents 11,000 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU. F1 · price: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. Read SEC document |
| May 07, 2018 Filed May 9, 2018 22:13 UTC | Neurogene Inc. AQXP · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $13.10 | $0.00 |
DisclosureSEC source: 0001209191-18-028974 · doc4.xml · derivative · entry 1 Nolan Sean P. · CIK 0001569926 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-05-06 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 1/12th of the total number of shares underlying the options on the one-month anniversary of May 7, 2018 (the "Vesting Commencement Date") and 1/12th of the total number of shares underlying the options each monthly anniversary of the Vesting Commencement Date thereafter for so long as the recipient of the option provides continuous service to the issuer, such that the total number of shares underlying the options shall be fully vested on the one-year anniversary of the Vesting Commencement Date. Read SEC document |
| March 13, 2018 Filed Mar 27, 2018 17:26 UTC | AveXis, Inc. AVXS · Entity 166664 | GrantEmployee Stock Option (Right to Buy) · Derivative | 44,000 | $0.00 Strike: $133.80 | $0.00 |
DisclosureSEC source: 0001209191-18-021776 · doc4.xml · derivative · entry 2 Nolan Sean P. · CIK 0001569926 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2028-03-13 F2 · derivative.exercise_date: The option shall vest and become exercisable as to 25% of the shares underlying the option on March 13, 2019; the remaining shares shall vest in 36 equal monthly installments beginning on April 13, 2019, subject to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document |
| March 13, 2018 Filed Mar 27, 2018 17:26 UTC | AveXis, Inc. AVXS · Entity 166664 | GrantCommon Stock | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-021776 · doc4.xml · nonDerivative · entry 1 Nolan Sean P. · CIK 0001569926 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 F1 · shares: These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares underlying this restricted stock award will vest in 3 equal annual installments beginning on March 13, 2019, such that the restricted stock award will be fully vested on March 13, 2021, subject to the Reporting Person's continuous service with the Issuer on each such date. F1 · price: These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares underlying this restricted stock award will vest in 3 equal annual installments beginning on March 13, 2019, such that the restricted stock award will be fully vested on March 13, 2021, subject to the Reporting Person's continuous service with the Issuer on each such date. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 17:04 UTC | AveXis, Inc. AVXS · Entity 166664 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $15.94 | $0.00 |
DisclosureSEC source: 0001209191-18-018544 · doc4.xml · derivative · entry 8 Nolan Sean P. · CIK 0001569926 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 728,300 Underlying: Common Stock · 10,000 shares Expires 2025-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: 184,575 shares vested and became exercisable on June 8, 2016; the remaining shares vest and become exercisable in 36 equal monthly installments thereafter until June 8, 2019, subject to the Reporting Person's continuous service with the Issuer on each such date. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 17:04 UTC | AveXis, Inc. AVXS · Entity 166664 | SaleCommon Stock | 1,100 | $131.86 | $145,046.00 |
DisclosureSEC source: 0001209191-18-018544 · doc4.xml · nonDerivative · entry 7 Nolan Sean P. · CIK 0001569926 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on November 29, 2017. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.33 to $132.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (7) to this Form 4. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 17:04 UTC | AveXis, Inc. AVXS · Entity 166664 | SaleCommon Stock | 600 | $130.78 | $78,468.00 |
DisclosureSEC source: 0001209191-18-018544 · doc4.xml · nonDerivative · entry 6 Nolan Sean P. · CIK 0001569926 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on November 29, 2017. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.32 to $131.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (6) to this Form 4. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 17:04 UTC | AveXis, Inc. AVXS · Entity 166664 | SaleCommon Stock | 4,800 | $129.66 | $622,368.00 |
DisclosureSEC source: 0001209191-18-018544 · doc4.xml · nonDerivative · entry 5 Nolan Sean P. · CIK 0001569926 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on November 29, 2017. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.23 to $130.225, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) to this Form 4. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 17:04 UTC | AveXis, Inc. AVXS · Entity 166664 | SaleCommon Stock | 2,400 | $128.65 | $308,760.00 |
DisclosureSEC source: 0001209191-18-018544 · doc4.xml · nonDerivative · entry 4 Nolan Sean P. · CIK 0001569926 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on November 29, 2017. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.21 to $129.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 17:04 UTC | AveXis, Inc. AVXS · Entity 166664 | SaleCommon Stock | 700 | $127.65 | $89,355.00 |
DisclosureSEC source: 0001209191-18-018544 · doc4.xml · nonDerivative · entry 3 Nolan Sean P. · CIK 0001569926 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,900 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on November 29, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.17 to $127.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 17:04 UTC | AveXis, Inc. AVXS · Entity 166664 | SaleCommon Stock | 400 | $126.65 | $50,660.00 |
DisclosureSEC source: 0001209191-18-018544 · doc4.xml · nonDerivative · entry 2 Nolan Sean P. · CIK 0001569926 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,600 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on November 29, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.15 to $126.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 17:04 UTC | AveXis, Inc. AVXS · Entity 166664 | Exercise / conversionCommon Stock | 10,000 | $15.94 | $159,400.00 |
DisclosureSEC source: 0001209191-18-018544 · doc4.xml · nonDerivative · entry 1 Nolan Sean P. · CIK 0001569926 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2017 Filed May 12, 2017 18:23 UTC | AveXis, Inc. AVXS · Entity 166664 | GrantEmployee Stock Option (Right to Buy) · Derivative | 96,000 | $0.00 Strike: $77.24 | $0.00 |
DisclosureSEC source: 0001209191-17-032145 · doc4.xml · derivative · entry 1 Nolan Sean P. · CIK 0001569926 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,000 Underlying: Common Stock · 96,000 shares Expires 2027-05-10 F1 · derivative.exercise_date: The option shall vest and become exercisable as to 25% of the shares underlying the option on May 10, 2018; the remaining shares shall vest in 36 equal monthly installments beginning on June 10, 2018, subject to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.